

Supplementary Figures

Supplementary Figures Legends

Supplementary Figure 1: Spectra of Detached, N- and O-linked Glycans from Serum and Recombinant Derived ITIH4

Supplementary Figure 2: Proteomic analyses and peptide identification of Serum and Recombinant ITIH4

Supplementary Figure 3: Extracted Ion Chromatogram (XIC) plots of ITIH4 glycopeptides treated with PNGaseF/H₂¹⁸O for site occupancy determination.

Supplementary Figure 4: Electron transfer dissociation (ETD) spectra of de-sialylated, mTRAQ-labeled glycopeptides IPKPEASFSPR+HexNAcHex and LAILPASAPPATSNPDPAVSR+HexNAc₂Hex₂.

Supplementary Figure 5: Table of all observed recombinant and serum-derived ITIH4 glycopeptides from CID MS/MS spectra, including (a) no exoglycosidase treatment, (b) after treatment with 2/3,6,8 neuraminidase, or (c) after treatment with 2/3,6,8 neuraminidase and alpha 1-3,4 fucosidase.


Supplementary Figure 1

Supplementary Figure 1 A

MALDI-TOF (MS) Spectra of Permethylated N-Glycans

N-linked Glycans from Recombinant ITIH4

4700 Reflector Spec #1[BP = 2606.2, 4246]




H:\GoldmanLab\KevinChandler\Data\KBC_274\KBC_274_280_MALDI_Glycans\KBC_280_07262013
D5_1_5500.T2D (HEK293 ITIH4 DETACHED, PERMETHYLATED N-GLYCANS)

Recombinant ITIH4 N-Glycan Relative Intensity

Peak (m/z)	Glycan	Relative Intensity (%)	Fuc (Y/N)	Fuc Intensity	NeuAc (Y/N)	NeuAc Intensity	Full NeuAc (Y/N)	Full NeuAc Intensity	2 Fuc (Y/N)	2 Fuc Intensity
1661.84	A2	0.1	0	0.0	0	0.0	0	0.0	0	0.0
2070.04	A2G2	1.3	0	0.0	0	0.0	0	0.0	0	0.0
2244.13	FA2G2	3.8	1	3.8	0	0.0	0	0.0	0	0.0
2285.15	FA3G1	1.4	1	1.4	0	0.0	0	0.0	0	0.0
2418.21	FA2F1G2	1.5	1	1.5	0	0.0	0	0.0	1	1.5
2431.21	A2G2S1	5.3	0	0.0	1	5.3	0	0.0	0	0.0
2489.25	FA3G2	1.4	1	1.4	0	0.0	0	0.0	0	0.0
2605.30	FA2G2S1	15.2	1	15.2	1	15.2	0	0.0	0	0.0
2646.33	FA3G1S1	2.5	1	2.5	1	2.5	0	0.0	0	0.0
2693.35	FA3G3	3.3	1	3.3	0	0.0	0	0.0	0	0.0
2792.38	A2G2S2	1.9	0	0.0	1	1.9	1	1.9	0	0.0
2850.43	FA3G2S1	1.4	1	1.4	1	1.4	0	0.0	0	0.0
2966.47	FA2G2S2	5.1	1	5.1	1	5.1	1	5.1	0	0.0
3054.53	FA3G3S1	10.4	1	10.4	1	10.4	0	0.0	0	0.0
3142.58	FA4G4	2.4	1	2.4	0	0.0	0	0.0	0	0.0
3228.61	FA3F1G3S1	1.2	1	1.2	1	1.2	0	0.0	1	1.2
3415.70	FA3G3S2	9.5	1	9.5	1	9.5	0	0.0	0	0.0
3503.75	FA4G4S1	7.4	1	7.4	1	7.4	0	0.0	0	0.0
3602.78	A3G3S3	2.0	0	0.0	1	2.0	1	2.0	0	0.0
3776.87	FA3G3S3	2.8	1	2.8	1	2.8	1	2.8	0	0.0
3864.93	FA4G4S2	13.6	1	13.6	1	13.6	0	0.0	0	0.0
4226.10	FA4G4S3	5.5	1	5.5	1	5.5	0	0.0	0	0.0
4587.27	FA4G4S4	0.8	1	0.8	1	0.8	1	0.8	0	0.0
		100.0		89.4		84.7		12.7		2.8

Detached Serum ITIH4 N-glycans



*incomplete permethylation

Supplementary Figure 1 B



Permethylated O-linked Glycans from Recombinant ITIH4

O-glycans - Full MS

KBC_ITIH4_cell_O-glycan-FT-2 #1 RT: 0.01

T: FTMS + c NSI Full ms [200.00-2000.00]

Fragmentation data also available, not shown









* non-glycan masses / contaminants




Supplementary Figure 1 C




Permethylated O-linked Glycans from Serum ITIH4





Structure		Permethylated (Na)			
		z=1	z=2	z=3	z=4
(Hex)1(HexNAc)1-OMe	Major structures	534.2591	278.6391	193.4227	150.8145
(NeuAc)1(Hex)1(HexNAc)1-OMe		895.4722	459.2259	313.8139	241.1079
(NeuAc)2(Hex)1(HexNAc)1-OMe		1256.9248	639.8128	434.2051	331.4013
(NeuAc)2(Hex)2(HexNAc)2-OMe	Minor structures	1705.8619	864.4258	583.9471	443.7078
(NeuAc)2(Hex)3(HexNAc)3-OMe		2155.0880	1089.0389	733.6892	556.0143











Supplementary Figure 2

Figure 2A: Recombinant ITIH4 Protein Identification (Trypsin Digest, MS/MS)

N	%Cov(95)	Accession	Species	Peptides(95%)
1	52.9	sp Q14624 ITIH4_HUMAN	HUMAN	166
2	22.51	sp P08238 HS90B_HUMAN	HUMAN	19
3	29.64	sp P08107 HSP71_HUMAN	HUMAN	21
4	33.07	sp P63261 ACTG_HUMAN	HUMAN	14
4	29.33	sp P60709 ACTB_HUMAN	HUMAN	13
5	12.12	sp P13639 EF2_HUMAN	HUMAN	11
6	22.46	sp P07195 LDHB_HUMAN	HUMAN	9
7	12.95	sp P14625 ENPL_HUMAN	HUMAN	12
8	17.74	sp P11021 GRP78_HUMAN	HUMAN	12
9	15.63	sp P14618 KPYM_HUMAN	HUMAN	8
10	22.17	sp Q71U36 TBA1A_HUMAN	HUMAN	9
10	22.17	sp P68363 TBA1B_HUMAN	HUMAN	9
11	9.276	sp O94985 CSTN1_HUMAN	HUMAN	8
12	13.33	sp Q08380 LG3BP_HUMAN	HUMAN	9
13	4.885	sp P01023 A2MG_HUMAN	HUMAN	9
14	15.21	sp P06733 ENOA_HUMAN	HUMAN	6
15	2.589	sp P49327 FAS_HUMAN	HUMAN	6
16	19.51	sp P04075 ALDOA_HUMAN	HUMAN	6
17	13.29	sp P07437 TBB5_HUMAN	HUMAN	6
18	4.972	sp P14543 NID1_HUMAN	HUMAN	5
19	9.852	sp P02768 ALBU_HUMAN	HUMAN	7
20	16.72	sp P04406 G3P_HUMAN	HUMAN	4
21	10.71	sp P16870 CBPE_HUMAN	HUMAN	5
22	17.49	sp P07900 HS90A_HUMAN	HUMAN	14
23	17.18	sp P11142 HSP7C_HUMAN	HUMAN	11
24	15.29	sp P62258 1433E_HUMAN	HUMAN	4
25	24.6	sp Q99880 H2B1L_HUMAN	HUMAN	4
25	24.6	sp Q8N257 H2B3B_HUMAN	HUMAN	4
25	24.6	sp Q16778 H2B2E_HUMAN	HUMAN	4
25	24.6	sp P33778 H2B1B_HUMAN	HUMAN	4
25	24.6	sp P23527 H2B1O_HUMAN	HUMAN	4
25	24.6	sp P06899 H2B1J_HUMAN	HUMAN	4
25	24.6	sp Q99879 H2B1M_HUMAN	HUMAN	4
25	24.6	sp Q99877 H2B1N_HUMAN	HUMAN	4
25	24.6	sp Q93079 H2B1H_HUMAN	HUMAN	4
25	24.6	sp Q5QNW6 H2B2F_HUMAN	HUMAN	4
25	24.6	sp P62807 H2B1C_HUMAN	HUMAN	4
25	24.6	sp P58876 H2B1D_HUMAN	HUMAN	4
25	24.6	sp P57053 H2BFS_HUMAN	HUMAN	4
25	24.6	sp O60814 H2B1K_HUMAN	HUMAN	4
26	9.779	sp Q8NHW5 RLAOL_HUMAN	HUMAN	3
26	9.779	sp P05388 RLA0_HUMAN	HUMAN	3
27	9.354	sp P10909 CLUS_HUMAN	HUMAN	3
28	21.36	sp P62805 H4_HUMAN	HUMAN	3
29	4.027	sp Q12906 ILF3_HUMAN	HUMAN	3

30	0.9423	sp P13611 CSPG2_HUMAN	HUMAN	3
31	17.47	sp P00338 LDHA_HUMAN	HUMAN	6
32	4.048	sp P34932 HSP74_HUMAN	HUMAN	3
33	5.774	sp P12277 KCRB_HUMAN	HUMAN	2
34	28.19	sp P62158 CALM_HUMAN	HUMAN	3
35	2.93	sp P22314 UBA1_HUMAN	HUMAN	3

Figure 2B: Serum ITIH4 Protein Identification (Trypsin Digest, MS/MS)

N	%Cov(95)	Accession	Species	Peptides(95%)
1	59.0	sp Q14624 ITIH4_HUMAN	HUMAN	56
2	27.9	sp P19823 ITIH2_HUMAN	HUMAN	20
3	12.6	sp P01024 CO3_HUMAN	HUMAN	14
4	18.1	sp P02768 ALBU_HUMAN	HUMAN	11
5	6.4	sp P0C0L5 CO4B_HUMAN	HUMAN	7
5	6.4	sp P0C0L4 CO4A_HUMAN	HUMAN	7
6	8.6	sp P19827 ITIH1_HUMAN	HUMAN	6
7	7.1	sp P04264 K2C1_HUMAN	HUMAN	4
8	20.6	sp P01857 IGHG1_HUMAN	HUMAN	5
9	9.6	sp P01876 IGHA1_HUMAN	HUMAN	3

Supplementary Figure 3

ITIH4 Occupancy Summary
Serum and Cell ITIH4

Part I:

N-glycosylation Site Occupancy in Serum-Derived ITIH4

- Serum-derived ITIH4 was treated with GluC and Trypsin, heated to denature proteases, then treated with PNGaseF in the presence of H₂¹⁸O
- 0.1 ug of the digest was injected onto an Eksigent ChromXP C18-CL interfaced with a 5600 TripleTOF mass spectrometer (ABSCIEX)
- Different chromatographic gradients were used (short gradient, 30 min; long gradient, 120 min)

Serum ITIH4 Occupancy Summary

Site	Peptide(s)	<i>m/z</i> (charge) Unlabeled	<i>m/z</i> (charge) Labeled	Serum ITIH4
N81	KAFIT <u>N</u> F (T,G)	420.734 (2+)	422.240 (2+)	+
N207	STFMTNQLVDALTTWQ <u>N</u> K (T,G)	700.014 (3+)	701.018 (3+)	>90%
N274	<u>N</u> VVFVIDK (T,G)	467.274 (2+)	468.780 (2+)	<1%
N517	LPTQ <u>N</u> ITFQTE (T,G)	646.330 (2+)	647.836 (2+)	>98%
N577	NQALNLSLAYSFVTPLTMVVTKPDDQE (T,G)	1027.853 (3+)	1028.857 (3+)	>95%

Serum ITIH4, N81


Site: N81 (Peptide: KAFITNF), Experiment: SerumITI4_PNGaseF_O18_1uL.wiff

Unlabeled (**420.73, 2+**) not detected, labeled (**422.24, 2+**) detected

Retention Time: 16.5 min (short gradient, 30 min)

- XIC of +TOF MS: Exp 1, 420.7 to 420.76 Da from Sample 1 (SerumITI4_PNGaseF_O18_1uL) of SerumITI4_PNGaseF_O18_1uL.wiff (Nanospray)
- XIC of +TOF MS: Exp 1, 422.21 to 422.27 Da from Sample 1 (SerumITI4_PNGaseF_O18_1uL) of SerumITI4_PNGaseF_O18_1uL.wiff (Nanospray)

XIC of +TOF MS: Exp 1, 420.7 to 420.76 Da from Sample 1 (SerumITI4_PNGaseF_O18_1uL) of SerumITI4_PNGaseF_O18_1uL.wiff... Max. 4.3e4 cps.



Peak at 16.2 min may be unlabeled peptide, but there is no MS2 data.


Note: In MS1, see 388 cps, or approx 7% of unlabeled peptide signal. Unlabeled ion may be at Retention Time 16.1957 min, m/z 420.73, 2+, but difficult to be confident because the isotope cluster is near the baseline

Serum ITIH4, N81

(N>D/O18)


KAFITNF.S

Labeled peptide observed, but low intensity. Unlabeled peptide (precursor and MS/MS) can not be found.



Fragmentation Evidence (peptide b- and y-ions) for N>D/O18 (3 Da shift) at glycosylation site

Residue	b	b+2	y	y+2
K	129.1022	65.0548	843.4735	422.2404
A	200.1394	100.5733	715.3785	358.1929
F	347.2078	174.1075	644.3414	322.6743
I	460.2918	230.6496	497.2730	249.1401
T	561.3395	281.1734	384.1889	192.5981
N[DelW]	678.3945	339.7009	283.1413	142.0743
F	825.4629	413.2351	166.0863	83.5468



O18 labeled KAFITNFSMII also found, (NOT SHOWN), VERY low abundance

Serum ITIH4, N207

Site: **N207 (Peptide: STFMTNQLVDALTTWQNK)** File: SerumITI4_PNGaseF_018_1uL.wiff


Unlabeled (**700.01, 3+**) not detected, labeled (**701.02, 3+**) detected

Retention Time: 19.5 min (short gradient, 30 min)

■ XIC of +TOF MS: Exp 1, 699.98 to 700.04 Da from Sample 1 (SerumITI4_PNGaseF_018_1uL) of SerumITI4_PNGaseF_018_1uL.wiff (Nanospray)

■ XIC of +TOF MS: Exp 1, 700.99 to 701.05 Da from Sample 1 (SerumITI4_PNGaseF_018_1uL) of SerumITI4_PNGaseF_018_1uL.wiff (Nanospray)

■ XIC of +TOF MS: Exp 1, 699.98 to 700.04 Da from Sample 1 (SerumITI4_PNGaseF_018_1uL) of SerumITI4_PNGaseF_018_1uL.wiff... Max. 7985.9 cps.




Note: In MS1, can't see unlabeled peptide. The labeled ion intensity max = 4000 cps at Retention Time 19.46 min. Can see an (unrelated) ion near, I=278 cps, good isotope cluster; if labeled peptide is present but lower than this ion, STFMTNQLVDALTTWQNK >90% occupancy

Site: N207 (Peptide: STFMTNQLVDALTTWQNK)

File: SerumITI4_PNGaseF_O18_1uL.wiff

Labeled (**701.02, 3+**) detected

Retention Time: 19.5 min (short gradient, 30 min)




Fragmentation Evidence (peptide b- and y-ions) for N>D/O18 (3 Da shift) at glycosylation site

Residue	b	b+2	y	y+2
N	682.2865	341.6469	1533.8032	767.4052
Q	810.3451	405.6762	1419.7602	710.3838
L	923.4291	462.2182	1291.7016	646.3545
V	1022.4975	511.7524	1178.6176	589.8124
D	1137.5245	569.2659	1079.5492	540.2782
A	1208.5616	604.7844	964.5222	482.7648
L	1321.6457	661.3265	893.4851	447.2462
T	1422.6933	711.8503	780.4010	390.7042
T	1523.7410	762.3741	679.3534	340.1803
W	1709.8203	855.4138	578.3057	289.6565
Q	1837.8789	919.4431	392.2264	196.6168
N[DeW]	1954.9339	977.9706	264.1678	132.5875
K	2083.0289	1042.0181	147.1128	74.0600

Site: N207 (Peptide: ALTTWQNK)

File: SerumITI4_PNGaseF_O18_1uL.wiff



Fragmentation Evidence (peptide b- and y-ions) for N>D/O18 (3 Da shift) at glycosylation site

Residue	b	b+2	y	y+2
A	72.0444	36.5258	964.5222	482.7648
L	185.1285	93.0679	893.4851	447.2462
T	286.1761	143.5917	780.4010	390.7042
T	387.2238	194.1155	679.3534	340.1803
W	573.3031	287.1552	578.3057	289.6565
Q	701.3617	351.1845	392.2264	196.6168
N[DeW]	818.4167	409.7120	264.1678	132.5875
K	946.5117	473.7595	147.1128	74.0600

Serum ITIH4, N274

Site: **N274 (Peptide: NVVFVIDK)** File: SerumITI4_PNGaseF_O18_1uL.wiff


Unlabeled (**467.27, 2+**) detected, labeled (**468.78, 2+**) not detected

Retention Time: 15.8 min (short gradient, 30 min)

■ XIC of +TOF MS: Exp 1, 467.24 to 467.3 Da from Sample 1 (SerumITI4_PNGaseF_O18_1uL) of SerumITI4_PNGaseF_O18_1uL.wiff (Nanospray)

■ XIC of +TOF MS: Exp 1, 468.75 Da from Sample 1 (SerumITI4_PNGaseF_O18_1uL) of SerumITI4_PNGaseF_O18_1uL.wiff (Nanospray)

■ XIC of +TOF MS: Exp 1, 467.24 to 467.3 Da from Sample 1 (SerumITI4_PNGaseF_O18_1uL) of SerumITI4_PNGaseF_O18_1uL.wiff... Max. 6.1e5 cps.




* **Note:** In MS1, see 1000 cps, or approx 1% of labeled peptide signal, and 8.3e4 cps unlabeled peptide intensity. Therefore, NVVFVIDK ~1% occupancy. This is about 1 min difference in Retention Time, larger than expected for short gradient, so we indicate <1% occupancy.

N274: NVVFVIDK Occupancy (N>D/O18)

Unlabeled peptide: 2+ (MW), 467.255 to 467.295

File: KBC_283_2_001_ITIH4_Serum_TG_PNGaseF_O18_1uL.wiff




Residue	b	b+2	y	y+2
N	115.0502	58.0287	933.5404	467.2738
V	214.1186	107.5629	819.4975	410.2524
V	313.1870	157.0972	720.4291	360.7182
F	460.2554	230.6314	621.3606	311.1840
V	559.3239	280.1656	474.2922	237.6498
I	672.4079	336.7076	375.2238	188.1155
D	787.4349	394.2211	262.1397	131.5735
K	915.5298	458.2686	147.1128	74.0600

N274: **N**VVFVIDK Occupancy (N>D/O18)

Labeled peptide: **2+** (MW), 468.740 to 468.780

File: KBC 283 2 001 ITIH4 Serum TG PNGaseF O18 1uL.wiff



Residue	b	b+2	y	y+2
N[DeW]	118.0623	59.5348	936.5525	468.7799
V	217.1307	109.0690	819.4975	410.2524
V	316.1991	158.6032	720.4291	360.7182
F	463.2675	232.1374	621.3606	311.1840
V	562.3359	281.6716	474.2922	237.6498
I	675.4200	338.2136	375.2238	188.1155
D	790.4469	395.7271	262.1397	131.5735
K	918.5419	459.7746	147.1128	74.0600

Fragmentation Evidence (peptide b- and y-ions) for N>D/O18 (3 Da shift) at glycosylation site

Serum ITIH4, N517


Site: N517 (Peptide: LPTQNITFQTE)

File: SerumITI4_PNGaseF_O18_1uL.wiff

LPTQNITFQTE – unlabeled (**646.33, 2+**) not detected, labeled (**647.84, 2+**) detected

Retention Time: 16.2 min (short gradient, 30 min)

- XIC of +TOF MS: Exp 1, 646.3 to 646.36 Da from Sample 1 (SerumITI4_PNGaseF_O18_1uL) of SerumITI4_PNGaseF_O18_1uL.wiff (Nanospray)
- XIC of +TOF MS: Exp 1, 647.81 to 647.87 Da from Sample 1 (SerumITI4_PNGaseF_O18_1uL) of SerumITI4_PNGaseF_O18_1uL.wiff (Nanospray)




Note: In MS1, there may be unlabeled peptide present at Retention Time 15.68 min (close to baseline), m/z 646.33,2+, Intensity= 1000 cps. LABELED peptide 4.5e4 cps. Therefore, occupancy >98% (based on intensity).

Serum ITIH4, N517: LPTQ NITFQTE Occupancy (N>D/O18)

Unlabeled peptide: 646.3277, 2+ (MW 1290.6395), 646.2877 to 646.3577

Labeled peptide: 647.8249, 2+ (MW 1293.6340), 647.7949 to 647.8549

File: KBC_283_2_001_ITIH4_Serum_TG_PNGaseF_O18_1uL.wiff



Fragmentation Evidence (peptide b- and y-ions) for N>D/O18 (3 Da shift) at glycosylation site

Residue	b	b+2	y	y+2
L	114.0913	57.5493	1294.6649	647.8361
P	211.1441	106.0757	1181.5809	591.2941
T	312.1918	156.5995	1084.5281	542.7677
Q	440.2504	220.6288	983.4804	492.2438
N[DeW]	557.3054	279.1563	855.4218	428.2146
I	670.3894	335.6983	738.3668	369.6871
T	771.4371	386.2222	625.2828	313.1450
F	918.5055	459.7564	524.2351	262.6212
Q	1046.5641	523.7857	377.1667	189.0870
T	1147.6118	574.3095	249.1081	125.0577
E	1276.6544	638.8308	148.0604	74.5339


Serum ITIH4, N577

Site: N577 (Peptide: NQALNLSLAYSFVTPLTMVVTKPDDQE) File: SerumITI4_PNGaseF_018_1uL.wiff

Unlabeled (**1027.85, 3+**) not detected, labeled (**1028.86, 3+**) detected

Retention Time: 20.45 min (short gradient, 30 min)


- XIC of +TOF MS: Exp 1, 1027.82 to 1027.88 Da from Sample 1 (SerumITI4_PNGaseF_018_1uL) of SerumITI4_PNGaseF_018_1uL.wiff (Nanospray)
- XIC of +TOF MS: Exp 1, 1028.83 to 1028.89 Da from Sample 1 (SerumITI4_PNGaseF_018_1uL) of SerumITI4_PNGaseF_018_1uL.wiff (Nanospray)



Note: In MS1, do not detect unlabeled peptide. Ions with a similar mass range at 150 cps can be observed. Therefore, if unlabeled peptide is below 150 cps, and LABELED peptide is at Intensity = 2734 cps, occupancy > 95%.

Site: N577 (Peptide: NQALNLSLAY) File: KBC_283_2_001_ITIH4_Serum_TG_PNGaseF_O18_1uL.wiff
Unlabeled (**553.80, 2+**) not detected, labeled (**555.30, 2+**) detected
Retention Time: 56.16-56.56 (long gradient, 120 min)

- XIC of +TOF MS: Exp 1, 553.77 to 553.83 Da from Sample 1 (SerumITIH4_PNGaseF_O18_1uL) of SerumITIH4_PNGaseF_O18_1uL.wiff (Nanospray)
- XIC of +TOF MS: Exp 1, 555.27 to 555.33 Da from Sample 1 (SerumITIH4_PNGaseF_O18_1uL) of SerumITIH4_PNGaseF_O18_1uL.wiff (Nanospray)




Note: Near the limit of detection. In MS1, the lowest ions could see the isotope cluster well were in Intensity = 150 cps range, or approx 10% of signal. So NQALNLSLAY >90% occupancy

Serum ITIH4, N577: NQALS**N**LSLAY Occupancy (N>D/O18)

Unlabeled peptide: **2+** (MW), to

Labeled peptide: **2+** (MW), to

File: KBC_283_2_001_ITIH4_Serum_TG_PNGaseF_O18_1uL.wiff



Residue	b	b+2	y	y+2
N	115.0502	58.0287	1109.5961	555.3017
Q	243.1088	122.0580	995.5532	498.2802
A	314.1459	157.5766	867.4946	434.2509
L	427.2300	214.1186	796.4575	398.7324
N[DeW]	544.2850	272.6461	683.3734	342.1904
L	657.3690	329.1881	566.3184	283.6629
S	744.4010	372.7042	453.2344	227.1208
L	857.4851	429.2462	366.2023	183.6048
A	928.5222	464.7648	253.1183	127.0628
Y	1091.5856	546.2964	182.0812	91.5442

Fragmentation Evidence (peptide b- and y-ions) for N>D/O18 (3 Da shift) at glycosylation site

Only modified peptide can be detected, but at low intensity.

SerumITIH4_PNGaseF_O18_1uL.wiff (Trypsin + GluC, PNGaseF/180)
Short gradient (30 min)
ProteinPilot results for peptides with N-glycosylation sites

Conf	Sequence	Modifications	Prec m/z	Theor m/z	Theor z	Time
0.1162	AFITNFSMIIDGMTYPGIK	Delta:H(1)O(-1)18O(1)(N)@5; Oxidation(M)@8	751.0446	751.0553	3	20.6795
0.9892	KAFITNF	Delta:H(1)O(-1)18O(1)(N)@6	422.2301	422.2404	2	16.5347
1.245	KAFITNFSMIID	Delta:H(1)O(-1)18O(1)(N)@6	701.8627	701.8741	2	18.7392
61.41	LPTQNITFQTE	Delta:H(1)O(-1)18O(1)(N)@5	647.8237	647.8361	2	16.2111
23.91	NQALNLSLAY	Delta:H(1)O(-1)18O(1)(N)@5	555.2905	555.3017	2	17.7469
99	NQALNLSLAYSFVTPLTSMVVTKPDDQE	Delta:H(1)O(-1)18O(1)(N)@5	1028.849	1028.857	3	20.4536
99	NVVFVID		403.2258	403.2263	2	17.9113
99	NVVFVIDK		467.2743	467.2738	2	15.8195
99	STFMTNQLVDALTTWQNK	Delta:H(1)O(-1)18O(1)(N)@17	701.0089	701.018	3	19.4746

KBC_283_2_001_ITIH4_Serum_TG_PNGaseF_O18_1uL.wiff

Long gradient (120 min)

ProteinPilot results for peptides with N-glycosylation sites

Conf	Sequence	Modifications	dMass	Prec m/z	Theor m/z	Theor z	Time
0.5414	ALTTWQNK	Delta:H(1)O(-1)18O(1)(N)@7	-0.02938	482.7501	482.7647	2	24.147
1.579	KAFITNF	Delta:H(1)O(-1)18O(1)(N)@6	-0.02425	422.2282	422.2404	2	47.1421
92.19	LPTQNITFQTE	Delta:H(1)O(-1)18O(1)(N)@5	-0.02375	647.8242	647.8361	2	45.648
0.005132	LPTQNITFQTE		-0.00621	646.327	646.3301	2	34.8314
42.69	NQALNLSLAY	Delta:H(1)O(-1)18O(1)(N)@5	-0.02232	555.2905	555.3017	2	56.2904
97.26	NVVFVID		-0.00266	403.225	403.2263	2	55.0064
2.741	NVVFVIDK	Delta:H(1)O(-1)18O(1)(N)@1	-0.02401	468.7679	468.7799	2	47.8217
99	NVVFVIDK		0.000511	467.2741	467.2738	2	43.4274
0.5379	TQNITFQTE	Delta:H(1)O(-1)18O(1)(N)@3	-0.02376	542.7558	542.7677	2	33.0738

Part II:

N-Glycosylation Site Occupancy In Recombinant ITIH4

- Recombinant ITIH4 was treated with GluC and Trypsin, (or Trypsin and Chymotrypsin) heated to denature proteases, then treated with PNGaseF in the presence of H_2^{18}O
- 0.1 ug of the digest was injected onto an Eksigent ChromXP C18-CL interfaced with a 5600 TripleTOF mass spectrometer (ABSCIEX)
- Different chromatographic gradients were used (short gradient, 30 min; long gradient, 120 min)

Recombinant ITIH4 Occupancy Summary

Site	Peptide(s)	<i>m/z</i> (charge) Unlabeled	<i>m/z</i> (charge) Labeled	Cell ITIH4
N81	KAFIT <u>N</u> F (T,G)	420.734 (2+)	422.240 (2+)	>80%
N207	MTNQLVDALTTWQ <u>N</u> K (T,C)	881.943 (3+)	883.449 (3+)	>97%
N274	<u>N</u> VVFVIDK (T,G)	467.274 (2+)	468.780 (2+)	<1%
N517	LPTQ <u>N</u> ITFQTE (T,G)	646.330 (2+)	647.836 (2+)	>99%
N577	NQAL <u>N</u> LSLAY (T,C)	553.796 (2+)	555.302 (3+)	>90%

Recombinant ITIH4, N81

Site: N81 (Peptide: KAFITNF) File: KBC_278_ITIH4_HEK_TG_PNGaseF_O18_1uL.wiff


Unlabeled peptide: 420.7360, 2+; Labeled peptide: 422.2291, 2+

Retention Time: 48 min (long gradient)

■ XIC of +TOF MS: Exp 1, 420.72 to 420.76 Da from Sample 1 (KBC_278_ITIH4_HEK_TG_PNGaseF_O18_1uL) of KBC_278_ITIH4_HEK_TG_PNGaseF_O18_1uL.wiff (Nanospray)

■ XIC of +TOF MS: Exp 1, 422.21 to 422.25 Da from Sample 1 (KBC_278_ITIH4_HEK_TG_PNGaseF_O18_1uL) of KBC_278_ITIH4_HEK_TG_PNGaseF_O18_1uL.wiff (Nanospray)

■ XIC of +TOF MS: Exp 1, 420.72 to 420.76 Da from Sample 1 (KBC_278_ITIH4_HEK_TG_PNGaseF_O18_1uL) of KBC_278_ITIH4_H... Max. 4662.0 cps.



Note: The unlabeled and labeled peptides differ in retention time by a larger-than-expected time. There is MS/MS evidence of the labeled peptide, therefore, we conclude that the Occupancy > 80%

Recombinant ITIH4, N207

Site N207: MTNQLVDALTTWQNK


KBC_288_004: HEK ITIH4 + Trypsin + Chymotrypsin + PNGaseF / O18

Unlabeled: 881.9432, 2+ not detected; **Labeled: 883.4493, 2+**

■ XIC of +TOF MS: Exp 1, 881.91 to 881.97 Da from Sample 1 (KBC_288_004_PNGaseFO18_1uL) of KBC_288_004_PNGaseFO18_1uL.wiff (Nanospray)

■ XIC of +TOF MS: Exp 1, 883.42 to 883.48 Da from Sample 1 (KBC_288_004_PNGaseFO18_1uL) of KBC_288_004_PNGaseFO18_1uL.wiff (Nanospray)

■ XIC of +TOF MS: Exp 1, 881.91 to 881.97 Da from Sample 1 (KBC_288_004_PNGaseFO18_1uL) of KBC_288_004_PNGaseFO18_1uL... Max. 8.0e4 cps.



NOTE: Labeled peptide detected at retention time 17.95 min, 9498 cps. Unlabeled peptide is not detected. In the MS spectrum near the expected retention time and m/z, I can see ions as low as about 284 cps. Therefore, estimate that non-labeled peptide is at most 3%, so occupancy is > 97%.


Recombinant ITIH4, N274

Site: **N274** (Peptide: **NVVFVIDK**) File: KBC_278_ITIH4_HEK_TG_PNGaseF_O18_1uL.wiff

Unlabeled (**467.27, 2+**) detected, labeled (**468.78, 2+**)

Retention Time: 42.5 min (long gradient, 120 min)

- XIC of +TOF MS: Exp 1, 467.24 to 467.3 Da from Sample 1 (HEKITI4_PNGaseF_O18_1uL) of HEKITI4_PNGaseF_O18_1uL.wiff (Nanospray)
- XIC of +TOF MS: Exp 1, 468.75 to 468.81 Da from Sample 1 (HEKITI4_PNGaseF_O18_1uL) of HEKITI4_PNGaseF_O18_1uL.wiff (Nanospray)



NOTE: Intensity of UNlabeled peptide is 7.7e4 (RT 42.3 min), and intensity of labeled peptide is 1e3 (RT 45.1 min). Therefore, occupancy = 2%. Different in retention time between unlabeled and labeled peptide is greater than expected. At N274, occupancy <1%

Recombinant ITIH4, N517

Site N517: LPTQNTFQTESSVAEQEAEF


KBC_288_004: HEK ITIH4 + Trypsin + Chymotrypsin + PNGaseF / O18

Unlabeled: 790.3763, 3+ not detected; **Labeled: 791.3803, 3+**

■ XIC of +TOF MS: Exp 1, 790.35 to 790.41 Da from Sample 1 (KBC_288_004_PNGaseFO18_1uL) of KBC_288_004_PNGaseFO18_1uL.wiff (Nanospray)

■ XIC of +TOF MS: Exp 1, 791.35 to 791.41 Da from Sample 1 (KBC_288_004_PNGaseFO18_1uL) of KBC_288_004_PNGaseFO18_1uL.wiff (Nanospray)

■ XIC of +TOF MS: Exp 1, 790.34 to 790.42 Da from Sample 1 (KBC_288_004_PNGaseFO18_1uL) of KBC_288_004_PNGaseFO18_1uL.wiff (Nanospray) Max. 1.1e4 cps.



NOTE: Intensity of labeled peptide is 1.9e5, cannot detect unlabeled peptide. Therefore, occupancy is >99%.

Recombinant ITIH4, N577

Site N577: NQALNLSLAY




KBC_288_004: HEK ITIH4 + Trypsin + Chymotrypsin + PNGaseF / O18

Unlabeled: 553.796. 2+; Labeled: 555.302. 2+

■ XIC of +TOF MS: Exp 1, 553.76 to 553.84 Da from Sample 1 (KBC_288_004_PNGaseFO18_1uL) of KBC_288_004_PNGaseFO18_1uL.wiff (Nanospray)

■ XIC of +TOF MS: Exp 1, 555.26 to 555.34 Da from Sample 1 (KBC_288_004_PNGaseFO18_1uL) of KBC_288_004_PNGaseFO18_1uL.wiff (Nanospray)

■ XIC of +TOF MS: Exp 1, 553.76 to 553.84 Da from Sample 1 (KBC_288_004_PNGaseFO18_1uL) of KBC_288_004_PNGaseFO18_1... Max. 9620.2 cps.



$$\begin{aligned} \% \text{ Occupancy} &= \\ &= (3.7e5) / (5.3e4 + 3.7e5) \\ &= 90\% \end{aligned}$$

HEK ITIH4 + Trypsin + GluC

Conf	Sequence	Modifications	Prec MW	Prec m/z	Theor MW	Theor m/z	Theor z	Time
99.0	LPTQNITFQTE	Delta:H(1)O(-1)18O(1)(N)@5	1293.63	647.82	1293.66	647.84	2	15.93
99.0	STFMTNQLVDALTTWQNK	Delta:H(1)O(-1)18O(1)(N)@17	2100.01	701.01	2100.03	701.02	3	19.32
45.6	NQALNLSLAY	Delta:H(1)O(-1)18O(1)(N)@5	1108.57	555.29	1108.59	555.30	2	17.60
0.5	KAFITNF	Delta:H(1)O(-1)18O(1)(N)@6	842.44	422.23	842.47	422.24	2	16.30

HEK ITIH4 + Trypsin + ChymoT

Conf	Sequence	Modifications	Prec MW	Prec m/z	Theor MW	Theor m/z	Theor z	Time
99.0	LPTQNITFQTESSVAEQEAEF	Delta:H(1)O(-1)18O(1)(N)@5	2371.10	791.37	2371.12	791.38	3	17.52
99.0	MTNQLVDALTTWQNK	Delta:H(1)O(-1)18O(1)(N)@14	1764.86	883.44	1764.88	883.45	2	17.97
99.0	NQALNLSLAY	Delta:H(1)O(-1)18O(1)(N)@5	1108.57	555.29	1108.59	555.30	2	17.54
98.9	RNQALNLSLAY	Delta:H(1)O(-1)18O(1)(N)@6	1264.67	633.34	1264.69	633.35	2	16.36


Supplementary Figure 4

Serum-Derived ITIH4 Glycopeptides (Desialylated) with ETD Fragmentation

IPKPEASFSPR + 2mTRAQ + Hex-HexNAc


L AILPASAPPATSNPDPAVSR + mTRAQ + Hex2HexNAc2

RT: 49.0331 - 54.3016




RB-KC-ITI4-Peps2-Desial-Targets #8679-8711 RT: 51.33-51.50 AV: 7 NL: 1.78E7

F: FTMS + p NSI Full ms [300.00-2000.00]




RT: 50.7869 - 51.9298






RB-KC-ITI4-Peps2-Desial-Targets #8685-8719 RT: 51.37-51.55 AV: 7 NL: 5.91E3

F: ITMS + c NSI Full ms 2 730.63@etd90.00 [50.00-2000.00]

LAILPASAPPATSNPDPVSR-HexNAc2Hex2-mTRAQ




◦: No modification
 *: Modified by HexNAcHex
 **: Modified by 2HexNAcHex




c^{+2}	c	z	z^{+2}			
138.1136	275.2200	1	L	21	---	---
173.6322	346.2571	2	A	20	2646.2642	1323.6357
230.1742	459.3411	3	I	19	2575.2271	1288.1172
---	---	4	L	18	2462.1430	1231.5751
335.2426	669.4780	5	P	17	---	---
370.7612	740.5151	6	A	16	2252.0062	1126.5067
596.8433	1192.6793	7	S(HexNAcHex)	15	2180.9691	1090.9882
---	---	8	A	14	1728.8048	864.9061
---	---	9	P	13	---	---
729.4146	1457.8219	10	P	12	---	---
764.9332	1528.8591	11	A	11	1463.6622	732.3347
998.0231	1995.0389	12	T(HexNAcHex)	10	1392.6251	696.8162
1041.5391	2082.0710	13	S	9	926.4452	463.7262
---	---	14	N	8	839.4132	420.2102
1147.0869	2293.1666	15	P	7	---	---
---	---	16	D	6	628.3175	314.6624
1253.1268	2505.2464	17	P	5	---	---
1288.6454	2576.2835	18	A	4	416.2378	208.6225
1338.1796	2675.3519	19	V	3	345.2007	173.1040
1381.6956	2762.3839	20	S	2	246.1323	123.5698
---	---	21	R	1	159.1002	80.0538

RT: 41.6020 - 47.9842




RB-KC-ITI4-Peps2-Desial-Targets #7613-7639 RT: 45.30-45.41 AV: 5 NL: 1.73E8

F: FTMS + p NSI Full ms [300.00-2000.00]




RT: 42.0663 - 47.7518



RB-KC-ITI4-Peps2-Desial-Targets #7595-7649 RT: 45.20-45.48 AV: 11 NL: 1.96E5




F: ITMS + c NSI Full ms2 628.01@etd90.00 [50.00-2000.00]



RB-KC-ITIH4
F: ITMS + c.N

c		144.102063	y	z
---	1	I	11	---
372.2727	2	P	10	1624.8186
---	3	K(144.102063)	9	1527.7659 1511.7472
741.5225	4	P	8	1255.5689
870.5651	5	E	7	1158.5161 1142.4974
941.6022	6	A	6	1029.4735 1013.4548
1393.7664	7	S(HexNAcHex)	5	958.4364 942.4177
1540.8349	8	F	4	506.2722 490.2534
---	9	S	3	359.2037 343.1850
1724.9196	10	P	2	272.1717
---	11	R	1	175.1190 159.1002

NL: 1.96E5



Supplementary Figure 5

Table of all observed recombinant and serum-derived ITIH4 glycopeptides from CID MS/MS spectra, including (a) no exoglycosidase treatment, (b) after treatment with 2/3,6,8 neuraminidase, or (c) after treatment with 2/3,6,8 neuraminidase and alpha 1-3,4 fucosidase.

Cell ITIH4 + Neuraminidase**AFITNFS (N81)**

Oxford	m/z (charge)	%
M5	964.90 (2+)	3
M6	1045.93 (2+)	2
A2	670.96 (3+)	1
	711.29 (3+)	5
A2G1	724.97 (3+)	2
	765.31 (3+)	4
A2G2	778.99 (3+)	64
A3G1	792.68 (3+)	3
FA2G2	827.67 (3+)	5
FA3G1	841.35 (3+)	4
A3G2	846.69 (3+)	3
A3G3	900.70 (3+)	4

ALTTWQNK (N207)

Oxford	m/z (charge)	%
FA2	802.69 (3+)	2
FA2G1	856.70 (3+)	3
FA2G2	910.72 (3+)	40
FA3G1	924.4 (3+)	23
	951.03 (3+)	8
FA2F1G2	959.41 (3+)	3
FA3F1G1	973.08 (3+)	16
FA3G2	978.42 (3+)	4
	986.76 (3+)	1

NVVFVIDK (N274)

Oxford	m/z (charge)	%
M5	717.33 (3+)	15
M6	771.34 (3+)	62
M7	825.36 (3+)	14
M8	879.38 (3+)	9

LPTQNITFQTE (N517)

Oxford	m/z (charge)	%
FA2	912.73 (3+)	3
FA2G1	966.75 (3+)	3
FA3	980.43 (3+)	<1
FA2G2	1020.77 (3+)	40
FA2F1G2	1069.46 (3+)	2
FA3G1	776.09 (4+)	3
FA3G1	1034.43 (3+)	9
FA3F1G1	1083.13 (3+)	4
FA3G2	1088.46 (3+)	4
FA3F1G2	1137.15 (3+)	<1
FA3G3	857.11 (4+)	17
FA3F1G3	1191.17 (3+)	<1
FA4G2	867.37 (4+)	3
FA4G4	948.40 (4+)	12

NQALNLSLAY (N577)

Oxford	m/z (charge)	%
FA2	851.04 (3+)	3
FA2G1	905.06 (3+)	3
FA2G2	959.07 (3+)	44
FA3G1	972.73 (3+)	15
FA3G3	810.85 (4+)	15
FA4G2	821.10 (4+)	5
FA4G4	902.13 (4+)	5
FA4F1G4	938.63 (4+)	7

HexNAc3Hex7Fuc1	999.41 (3+)	3
IPKPEASFSPR (S640, S642)		
Oxford	m/z (charge)	%
HexNAc1Hex1	531.95 (3+)	93
HexNAc1Hex4	694.04 (3+)	7
GPDVLTATVSGK (T506, T508, S510)		
Oxford	m/z (charge)	%
HexNAc1Hex1	755.37 (2+)	6
HexNAc2Hex2	625.63 (3+)	67
HexNAc1Hex4	665.96 (3+)	4
HexNAc1Hex1NeuAc1	600.96 (3+)	23
Cell ITIH4 + Neuraminidase + a1-3,4 Fucosidase		
Oxford	m/z (charge)	%
M5	964.90 (2+)	3
M6	1045.93 (2+)	2
A2	670.96 (3+)	1
	711.29 (3+)	5
A2G1	724.97 (3+)	3
	765.31 (3+)	3
A2G2	778.99 (3+)	66
A3G1	792.68 (3+)	5
FA2G2	827.67 (3+)	1
FA3G1	841.35 (3+)	3
A3G2	846.69 (3+)	4
A3G3	900.70 (3+)	4
ALTTWQNK (N207)		
Oxford	m/z (charge)	%
A2	754.00 (3+)	<1
FA2	802.69 (3+)	2
A2G1	808.01 (3+)	<1
FA2G1	856.70 (3+)	2
A2G2	862.03 (3+)	1
FA2G2	910.72 (3+)	42
A3G1	875.71 (3+)	<1
FA3G1	924.4 (3+)	39
	951.03 (3+)	5
FA2F1G2	959.41 (3+)	<1
A3G2	929.73 (3+)	<1
FA3G2	978.42 (3+)	3
HexNAc6Hex3Fuc1	938.07 (3+)	5
NVVFVIDK (N274)		
Oxford	m/z (charge)	%
M5	717.33 (3+)	15
M6	771.34 (3+)	66
M7	825.36 (3+)	11
M8	879.38 (3+)	9
LPTQNITFQTE (N517)		
Oxford	m/z (charge)	%
A2	864.05 (3+)	<1
FA2	912.73 (3+)	3
A2G1	918.07 (3+)	<1
FA2G1	966.75 (3+)	3
A2G2	972.08 (3+)	<1
FA2G2	1020.77 (3+)	41
FA2F1G2	1069.46 (3+)	<1
FA3	980.43 (3+)	1
FA3G1	776.09 (4+)	13

FA3F1G1	1083.13 (3+)	<1
FA3G2	1088.46 (3+)	4
FA3F1G2	1137.15 (3+)	<1
A3G3	1093.79 (3+)	<1
FA3G3	857.11 (4+)	15
FA3F1G3	1191.17 (3+)	<1
A4G2	867.37 (4+)	3
A4G4	1215.52 (3+)	<1
FA4G4	948.40 (4+)	14
<i>NQAL NLSLAY (N577)</i>		
Oxford	<i>m/z (charge)</i>	%
FA2	851.04 (3+)	3
FA2G1	905.06 (3+)	3
FA2G2	959.07 (3+)	46
FA3G1	972.73 (3+)	10
A3G3	774.34 (4+)	2
FA3G3	810.85 (4+)	15
A4G2	784.59 (4+)	1
FA4G2	821.10 (4+)	3
A4G4	853.47 (4+)	2
FA4G4	902.13 (4+)	6
FA4F1G4	938.63 (4+)	6
HexNAc3Hex7Fuc1	999.41 (3+)	3
<i>IPKPEASFSPR (S640, S642)</i>		
Oxford	<i>m/z (charge)</i>	%
HexNAc1Hex1	531.95 (3+)	95
HexNAc1Hex4	694.04 (3+)	5
<i>GPDVLTATVSGK (T506, T508, S510)</i>		
Oxford	<i>m/z (charge)</i>	%
HexNAc1Hex1	755.37 (2+)	4
HexNAc2Hex2	625.63 (3+)	66
HexNAc1Hex4	665.96 (3+)	4
HexNAc1Hex1NeuAc1	600.96 (3+)	26

Serum ITIH4 + Neuraminidase		
KAFITNF (N81)		
Oxford	m/z (charge)	%
A2G2	821.70 (3+)	82
A2F1G2	870.37 (3+)	7
A3G3	943.39 (3+)	11
ALTTWQNK (N207)		
Oxford	m/z (charge)	%
A2G2	862.04 (3+)	100
NVVFVIDK (N274)		
Oxford	m/z (charge)	%
M5	717.32 (3+)	25
M6	771.34 (3+)	75
LPTQNITFQTE (N517)		
Oxford	m/z (charge)	%
A2G2	729.31 (4+)	64
	972.08 (3+)	
FA2G2	765.82 (4+)	3
	1020.77 (3+)	
A3G3	820.59 (4+)	23
	1093.78 (3+)	
FA3G3	857.11 (4+)	9
	1142.48 (3+)	
FA3F1G3	893.63 (4+)	<1
	1191.17 (3+)	
A4G4	911.89 (4+)	<1
	1215.52 (3+)	
NQALNLSLAY (N577)		
Oxford	m/z (charge)	%
A2G2	683.04 (4+)	84
	910.38 (3+)	
A3G3	774.34 (4+)	16
	1032.34 (3+)	
A3F1G3	1080.80 (3+)	<1
Serum ITIH4 + Neuraminidase + α1-3,4 Fucosidase		
KAFITNF (N81)		
Oxford	m/z (charge)	%
A2G2	821.70 (3+)	87
FA2G2	870.37 (3+)	3
A3G3	943.39 (3+)	10
ALTTWQNK (N207)		
Oxford	m/z (charge)	%
A2G2	862.04 (3+)	100
NVVFVIDK (N274)		
Oxford	m/z (charge)	%
M5	717.32 (3+)	30
M6	771.34 (3+)	70
LPTQNITFQTE (N517)		
Oxford	m/z (charge)	%
A2G2	729.31 (4+)	65
	972.08 (3+)	
FA2G2	765.82 (4+)	3
	1020.77 (3+)	

A3G3	820.59 (4+)	29
FA3G3	857.11 (4+)	2
	1142.48 (3+)	
FA3F1G3	893.63 (4+)	<1
	1191.17 (3+)	
A4G4	911.89 (4+)	1
	1215.52 (3+)	
<i>NQALNLSLAY (N577)</i>		
Oxford	<i>m/z (charge)</i>	%
A2G2	683.04 (4+)	84
	910.39 (3+)	
A3G3	774.34 (4+)	16
	1032.34 (3+)	